Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

[1]  Stephen L. Abrams,et al.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2013, Leukemia.

[2]  K. Turksen,et al.  Epidermal Cells , 2014, Methods in Molecular Biology.

[3]  David R. Jones,et al.  PtdIns5P and Pin1 in oxidative stress signaling. , 2013, Advances in biological regulation.

[4]  T. Hunt.  On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis. , 2013, Advances in biological regulation.

[5]  Jayson A. Neil,et al.  Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. , 2013, Advances in biological regulation.

[6]  J. Barata,et al.  IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. , 2013, Advances in biological regulation.

[7]  John E. Burke,et al.  Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS) , 2013, Advances in biological regulation.

[8]  David J. Fleet,et al.  Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.

[9]  N. Heerema,et al.  Characterization of the role of Fhit in suppression of DNA damage. , 2013, Advances in biological regulation.

[10]  C. Erneux,et al.  SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. , 2013, Advances in biological regulation.

[11]  S. Ryu,et al.  Phospholipase C-γ1 involved in brain disorders. , 2013, Advances in biological regulation.

[12]  Huanchen Wang,et al.  Structural insight into inositol pyrophosphate turnover. , 2013, Advances in biological regulation.

[13]  A. Perrakis,et al.  Structure-function relationships of autotaxin, a secreted lysophospholipase D. , 2013, Advances in biological regulation.

[14]  Hana L. Goldschmidt,et al.  Diacylglycerol kinase θ: regulation and stability. , 2013, Advances in biological regulation.

[15]  H. Ichijo,et al.  Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. , 2013, Advances in biological regulation.

[16]  J. McCubrey,et al.  Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. , 2013, Advances in biological regulation.

[17]  J. McCubrey,et al.  Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. , 2013, Advances in biological regulation.

[18]  A. Burlingame,et al.  Receptor tyrosine kinase signaling mechanisms: Devolving TrkA responses with phosphoproteomics. , 2013, Advances in biological regulation.

[19]  S. Schurmans,et al.  Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells. , 2013, Advances in biological regulation.

[20]  J. Boultwood,et al.  Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. , 2013, Advances in biological regulation.

[21]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance , 2012, Oncotarget.

[22]  P. S. Klein,et al.  Maintenance of Hematopoietic Stem Cells through Regulation of Wnt and mTOR Pathways , 2012, Nature Medicine.

[23]  P. Pandolfi,et al.  A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance , 2012, Nature Medicine.

[24]  S. K. Zaidi,et al.  Epigenetic mechanisms in leukemia. , 2012, Advances in biological regulation.

[25]  P. Berggren,et al.  The pancreatic beta cell as a paradigm for advances in inositide research. , 2012, Advances in biological regulation.

[26]  E. Hirsch,et al.  PI3K keeps the balance between metabolism and cancer. , 2012, Advances in biological regulation.

[27]  Stephen L. Abrams,et al.  Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response , 2012, Oncotarget.

[28]  V. Bilim,et al.  GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). , 2012, Biochemical and biophysical research communications.

[29]  I. Shin,et al.  Glycogen synthase kinase 3-β phosphorylates novel S/T-P-S/T domains in Notch1 intracellular domain and induces its nuclear localization. , 2012, Biochemical and biophysical research communications.

[30]  J. McCubrey,et al.  Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies , 2012, Expert opinion on therapeutic targets.

[31]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[32]  W. Zhou,et al.  ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. , 2012, Cancer letters.

[33]  Sejeong Shin,et al.  Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1) , 2012, Cell cycle.

[34]  S. Cagnol,et al.  Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. , 2012, Carcinogenesis.

[35]  Gabriela Alexe,et al.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. , 2012, The Journal of clinical investigation.

[36]  K. Inoki,et al.  AMPK and mTOR in cellular energy homeostasis and drug targets. , 2012, Annual review of pharmacology and toxicology.

[37]  L. Sun,et al.  GSK3 is a regulator of RAR-mediated differentiation , 2012, Leukemia.

[38]  J. McCubrey,et al.  AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications , 2012, Leukemia.

[39]  R. Irvine,et al.  The activity, evolution and association of phosphatidylinositol 5-phosphate 4-kinases. , 2012, Advances in biological regulation.

[40]  V. Bankaitis,et al.  Thoughts on Sec14-like nanoreactors and phosphoinositide signaling. , 2012, Advances in biological regulation.

[41]  Stephen L. Abrams,et al.  Novel approaches to target cancer initiating cells-eliminating the root of the cancer. , 2012, Advances in biological regulation.

[42]  Y. Kanaho,et al.  Regulation and functions of the lipid kinase PIP5K g661 at synapses. , 2012, Advances in biological regulation.

[43]  J. Putney,et al.  Phospholipase C signaling and calcium influx. , 2012, Advances in biological regulation.

[44]  J. McCubrey,et al.  PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. , 2012, Advances in biological regulation.

[45]  J. Edwards,et al.  Targeting sphingosine kinase 1 in cancer. , 2012, Advances in biological regulation.

[46]  K. E. van der Vos,et al.  Regulation of autophagy by Forkhead box (FOX) O transcription factors. , 2012, Advances in Biological Regulation.

[47]  P. Majerus,et al.  The role of myotubularin-related phosphatases in the control of autophagy and programmed cell death. , 2012, Advances in biological regulation.

[48]  C. Mitchell,et al.  INPP4A/INPP4B and P-Rex proteins: related but different? , 2012, Advances in biological regulation.

[49]  S. Ryu,et al.  Diverse cellular and physiological roles of phospholipase C-γ1. , 2012, Advances in biological regulation.

[50]  A. Toker.  Achieving specificity in Akt signaling in cancer. , 2012, Advances in biological regulation.

[51]  J. McCubrey,et al.  Revisiting nuclear phospholipase C signalling in MDS. , 2012, Advances in biological regulation.

[52]  J. Saba,et al.  Truth and consequences of sphingosine-1-phosphate lyase. , 2012, Advances in biological regulation.

[53]  I. Batty,et al.  Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. , 2012, Advances in biological regulation.

[54]  Y. Choi,et al.  Loss of Akt1 evokes epithelial-mesenchymal transition by autocrine regulation of transforming growth factor-β1. , 2012, Advances in biological regulation.

[55]  M. Laguerre,et al.  Role of the C-terminal regulatory domain in the allosteric inhibition of PKB/Akt. , 2012, Advances in biological regulation.

[56]  L. Mei,et al.  Essential role of PIKE GTPases in neuronal protection against excitotoxic insults. , 2012, Advances in biological regulation.

[57]  Y. Shirai,et al.  Regulation of diacylglycerol kinase by phosphorylation. , 2012, Advances in biological regulation.

[58]  M. Falasca,et al.  Phosphoinositides signalling in cancer: focus on PI3K and PLC. , 2012, Advances in biological regulation.

[59]  L. Amoasii,et al.  Primary T-tubule and autophagy defects in the phosphoinositide phosphatase Jumpy/MTMR14 knockout mice muscle. , 2012, Advances in biological regulation.

[60]  H. Ichijo,et al.  Activation mechanisms of ASK 1 in response to various stresses and its signi fi cance in intracellular signaling , 2012 .

[61]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[62]  Christian Hölscher,et al.  GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease , 2012, Reviews in the neurosciences.

[63]  L. Platanias,et al.  AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications , 2011, Oncotarget.

[64]  S. Habib.  Mechanism of Activation of AMPK and Upregulation of OGG1 by Rapamycin in Cancer Cells , 2011, Oncotarget.

[65]  B. Martín-Castillo,et al.  Metformin: Multi-faceted protection against cancer , 2011, Oncotarget.

[66]  E. Buss,et al.  Leukemia stem cells , 2011, International journal of cancer.

[67]  J. Blenis,et al.  Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation , 2011, Proceedings of the National Academy of Sciences.

[68]  G. Cooper,et al.  A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells , 2011, Cell cycle.

[69]  Hans van Dam,et al.  GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb , 2011, Molecular biology of the cell.

[70]  L. Ellisen,et al.  Feedback Control of p53 Translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage Response , 2011, Molecular and Cellular Biology.

[71]  T. Shimura.  Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. , 2011, Journal of radiation research.

[72]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[73]  R. Belmaker,et al.  The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. , 2011, Current pharmaceutical design.

[74]  C. Sutherland.  What Are the bona fide GSK3 Substrates? , 2011, International journal of Alzheimer's disease.

[75]  Carlos A. Garcia,et al.  Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3-β–Signaling Pathways Regulates the Innate Inflammatory Response , 2011, The Journal of Immunology.

[76]  J. McCubrey,et al.  Targeting the cancer initiating cell: the Achilles' heel of cancer. , 2011, Advances in enzyme regulation.

[77]  J. McCubrey,et al.  The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). , 2011, Advances in enzyme regulation.

[78]  Weiguo Lu,et al.  Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance , 2010, International Journal of Gynecologic Cancer.

[79]  C. So,et al.  β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. , 2010, Cancer cell.

[80]  L. Chin,et al.  LKB1 regulates quiescence and metabolic homeostasis of hematopoietic stem cells , 2010, Nature.

[81]  A. Trumpp,et al.  Tuning mTORC1 activity for balanced self-renewal and differentiation. , 2010, Developmental cell.

[82]  S. Rafii,et al.  Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1 , 2010, Cell.

[83]  N. Zeleznik-Le,et al.  Glycogen synthase kinase-3 and leukemia: restoring the balance. , 2010, Cancer cell.

[84]  Kevin S. Smith,et al.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.

[85]  Dianqing Wu,et al.  GSK3: a multifaceted kinase in Wnt signaling. , 2010, Trends in biochemical sciences.

[86]  Rajakishore Mishra.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer , 2010, Molecular Cancer.

[87]  W. Tong,et al.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.

[88]  P. Fletcher,et al.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice , 2009, Molecular Brain.

[89]  H. Miki,et al.  Sufu recruits GSK3beta for efficient processing of Gli3. , 2009, Biochemical and biophysical research communications.

[90]  J. Dick,et al.  PLZF is a regulator of homeostatic and cytokine-induced myeloid development. , 2009, Genes & development.

[91]  Ze'ev Ronai,et al.  REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase , 2009, EMBO reports.

[92]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[93]  Andreas Trumpp,et al.  Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair , 2008, Cell.

[94]  L. Hood,et al.  Dysregulated gene expression networks in human acute myelogenous leukemia stem cells , 2009, Proceedings of the National Academy of Sciences.

[95]  Hee-Sae Park,et al.  Beta-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. , 2009, Biochimica et biophysica acta.

[96]  Kwonseop Kim,et al.  Regulation of Notch1/NICD and Hes1 expressions by GSK-3α/β , 2009, Molecules and cells.

[97]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[98]  P. Lio’,et al.  Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair , 2008, Cell.

[99]  David A. Williams,et al.  mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization , 2008, Proceedings of the National Academy of Sciences.

[100]  J. Woodgett,et al.  Glycogen synthase kinase-3 and cancer: good cop, bad cop? , 2008, Cancer cell.

[101]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[102]  R. Evans,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.

[103]  Yang Liu,et al.  TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species , 2008, The Journal of experimental medicine.

[104]  R. Dolcetti,et al.  GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma , 2008 .

[105]  Maria M. Mihaylova,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.

[106]  Jieun Song,et al.  Down‐regulation of Notch‐dependent transcription by Akt in vitro , 2008, FEBS letters.

[107]  Gustavo Pedraza-Alva,et al.  Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation , 2008, Science.

[108]  I. Weissman,et al.  Stems Cells and the Pathways to Aging and Cancer , 2008, Cell.

[109]  A. Dar,et al.  t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. , 2008, Cancer research.

[110]  Chika Yokota,et al.  Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions , 2007, Development.

[111]  R. Dolcetti,et al.  GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. , 2008, Cell cycle.

[112]  W. Birchmeier,et al.  Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. , 2008, Blood.

[113]  B. Doble,et al.  Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. , 2007, Cell metabolism.

[114]  M. Cleary,et al.  Protein arginine-methyltransferase-dependent oncogenesis , 2007, Nature Cell Biology.

[115]  M. Ding,et al.  The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. , 2007, Cancer research.

[116]  J. V. Vanden Heuvel,et al.  Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.

[117]  Helene Maccario,et al.  PTEN is destabilized by phosphorylation on Thr366. , 2007, The Biochemical journal.

[118]  B. Doble,et al.  Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines , 2007 .

[119]  M. Cortés-Canteli,et al.  NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders , 2007, The Journal of Neuroscience.

[120]  Anne-Claude Gingras,et al.  Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling , 2007, Science.

[121]  J. Clapham,et al.  Thermogenic and metabolic antiobesity drugs: rationale and opportunities , 2007, Diabetes, obesity & metabolism.

[122]  J. Licht,et al.  HOX deregulation in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[123]  H Phillip Koeffler,et al.  RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. , 2007, Experimental hematology.

[124]  O. Ilkayeva,et al.  Glycogen Synthase Kinase 3α and 3β Mediate a Glucose-Sensitive Antiapoptotic Signaling Pathway To Stabilize Mcl-1 , 2007, Molecular and Cellular Biology.

[125]  H. Miki,et al.  GSK3beta positively regulates Hedgehog signaling through Sufu in mammalian cells. , 2007, Biochemical and biophysical research communications.

[126]  M. MacCoss,et al.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. , 2007, Science.

[127]  A. Xu,et al.  Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. , 2006, Cancer research.

[128]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[129]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[130]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[131]  B. Ponsioen,et al.  GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. , 2006, Molecular biology of the cell.

[132]  M. Hung,et al.  Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization , 2006, Molecular and Cellular Biology.

[133]  Xi He,et al.  A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation , 2005, Nature.

[134]  Christof Niehrs,et al.  Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transduction , 2005, Nature.

[135]  E. Liu,et al.  Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. , 2005, Cancer research.

[136]  Bin Zhang,et al.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. , 2005, Biochemical and biophysical research communications.

[137]  R. Cardiff,et al.  Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. , 2005, Cancer research.

[138]  M. Burdick,et al.  Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. , 2005, Cancer research.

[139]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[140]  G. Mills,et al.  Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. , 2005, Cancer research.

[141]  A. G. de Herreros,et al.  Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription , 2005, The Journal of cell biology.

[142]  K. Woodcroft,et al.  Insulin and Growth Factor Signaling , 2005 .

[143]  T. Laessig,et al.  Glycogen Synthase Kinase-3β Phosphorylates Bax and Promotes Its Mitochondrial Localization during Neuronal Apoptosis , 2004, The Journal of Neuroscience.

[144]  P. Pandolfi,et al.  Essential role of Plzf in maintenance of spermatogonial stem cells , 2004, Nature Genetics.

[145]  P. Greengard,et al.  Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor , 2004, Nature Medicine.

[146]  Adam Cole,et al.  Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. , 2004, The Biochemical journal.

[147]  L. Espinosa,et al.  Phosphorylation by Glycogen Synthase Kinase-3β Down-regulates Notch Activity, a Link for Notch and Wnt Pathways* , 2003, Journal of Biological Chemistry.

[148]  James M. Roberts,et al.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.

[149]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[150]  I. Weissman,et al.  MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. , 2003, Cancer cell.

[151]  T. Dale,et al.  The Regulation of Glycogen Synthase Kinase-3 Nuclear Export by Frat/GBP* , 2002, The Journal of Biological Chemistry.

[152]  T. Rabbitts,et al.  The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. , 2002, Trends in molecular medicine.

[153]  Daniel R. Foltz,et al.  Glycogen Synthase Kinase-3β Modulates Notch Signaling and Stability , 2002, Current Biology.

[154]  Hans Clevers,et al.  Wnt Signaling Controls the Phosphorylation Status of β-Catenin* , 2002, The Journal of Biological Chemistry.

[155]  D. M. Ferkey,et al.  Glycogen Synthase Kinase-3β Mutagenesis Identifies a Common Binding Domain for GBP and Axin* , 2002, The Journal of Biological Chemistry.

[156]  A. Zeiher,et al.  Glycogen Synthase Kinase-3 Couples AKT-dependent Signaling to the Regulation of p21Cip1 Degradation* , 2002, The Journal of Biological Chemistry.

[157]  A. Reith,et al.  The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation , 2001 .

[158]  R. Jope,et al.  Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3β* , 2001, The Journal of Biological Chemistry.

[159]  G. Johnson,et al.  Glycogen Synthase Kinase 3β Is Tyrosine Phosphorylated by PYK2 , 2001 .

[160]  A. Reith,et al.  The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. , 2001, Structure.

[161]  G. Johnson,et al.  Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. , 2001, Biochemical and biophysical research communications.

[162]  I. Grundke‐Iqbal,et al.  Role of protein phosphatase‐2A and ‐1 in the regulation of GSK‐3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain , 2000, FEBS letters.

[163]  A Zelent,et al.  Two critical hits for promyelocytic leukemia. , 2000, Molecular cell.

[164]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[165]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[166]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[167]  M. Hung,et al.  b-Catenin , a novel prognostic marker for breast cancer : Its roles in cyclin D 1 expression and cancer progression , 2000 .

[168]  E. Abraham.  NF-kappaB activation. , 2000, Critical care medicine.

[169]  D. Krause,et al.  Mammalian Suppressor-of-Fused modulates nuclear–cytoplasmic shuttling of GLI-1 , 1999, Nature Cell Biology.

[170]  R. Jope,et al.  Insulin Transiently Increases Tau Phosphorylation , 1999, Journal of neurochemistry.

[171]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[172]  Unnur Thorsteinsdottir,et al.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.

[173]  Akira Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin , 1998 .

[174]  A. Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. , 1998, The EMBO journal.

[175]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[176]  P. Polakis,et al.  Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. , 1996, Science.

[177]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[178]  J. Bartek,et al.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. , 1995, Cancer letters.

[179]  J. Woodgett,et al.  Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. , 1994, The Biochemical journal.

[180]  H. Creasey,et al.  Treatment of Alzheimer's disease: Authors' reply. , 1994 .

[181]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[182]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[183]  P. Cohen,et al.  Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. , 1993, The Biochemical journal.

[184]  J. Woodgett,et al.  Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation. , 1993, The EMBO journal.

[185]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[186]  J. Lefante,et al.  Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia A Southeastern Cancer Study Group study , 1984, American journal of clinical oncology.

[187]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.

[188]  M. Kameyama,et al.  [Nervous system diseases of the aged]. , 1981, Nihon rinsho. Japanese journal of clinical medicine.